Home | Pharma Manufacturing

5/1/2026

The framework for the development and approval of individualized therapies for genetic conditions has significant chemistry, manufacturing, and controls hurdles.

4/30/2026

The Morrisville site, part of a $23 billion investment in U.S. operations, will enable end‑to‑end manufacturing for all advanced technology platforms domestically.

4/29/2026

For large pharmaceutical companies, the chemistry, manufacturing, and control (CMC) process is a key constraint compared to conventional therapies.

4/28/2026

From prefilled syringes to autoinjectors, the CDMO is expanding capacity in the U.S. and Europe as self-administered therapies gain traction.

4/27/2026

The Chengdu facility, which will be equipped with a 15,000L fermenter, is slated for Good Manufacturing Practice readiness for production by the end of the year.

4/24/2026

Chinese innovation continues in some of the most technically demanding modalities, including antibody-drug conjugates and multi-specific antibodies.

4/23/2026

The drugmaker’s 185-acre hub, expected to be completed by the end of 2028, will support production of its immunology, neuroscience, and oncology medicines.

4/22/2026

To grow its worldwide network, Lilly decided to scale its production sites with standardization, drawing upon lessons learned from its existing plant sites.

4/21/2026

The company’s new platform uses unfertilized chicken eggs to produce therapeutic proteins, challenging Chinese hamster ovary cell production models.

4/20/2026

The CDMO has invested in its Le Mans, France site, which it contends is one of the world’s leading facilities for antibody-drug conjugate and cytotoxic drug manufacturing.

4/17/2026

The proposal also includes $9 million and 19 new full-time positions for the U.S. Food and Drug Administration to accelerate advanced pharmaceutical manufacturing.

4/16/2026

The new 2,000‑square‑meter quality control lab at its production facility in Hillerød, Denmark is designed to support the site’s bioreactor expansion.

4/15/2026

The facility, slated to be GMP-ready in 2027, will house one of Japan’s largest single-use bioreactor systems for mammalian production, according to the company.

4/14/2026

New data from USP reveals that 48 of the 100 vulnerable U.S. medicines are dependent on a key starting material sourced from at least one country.

4/13/2026

Lilly’s total Chinese investment has reached nearly $6 billion, including $3 billion over the next decade to build a localized manufacturing and supply network.

4/10/2026

The biopharmaceutical industry’s funding trends, product pipeline, and pace of R&D spending indicate demand is set to improve this year, say William Blair analysts.

4/9/2026

Biopharma companies are increasingly choosing to outsource manufacturing for the U.S. market to European facilities, finds data and analytics firm GlobalData.

4/8/2026

Rising oil prices and disrupted shipping routes drove up costs, delaying sensitive shipments, and forcing pharmaceutical companies to rethink supply chain strategy.

4/7/2026

While its advanced synthesis and integrated biologics platforms drove strong growth in 2025, the company’s specialized modalities sales declined versus the prior year.

4/6/2026

Leerink Partners analysts see no near-term material changes to U.S. onshoring narrative, given Trump’s executive order late last week on pharmaceutical imports.

4/3/2026

Drug companies with Most Favored Nation pricing deals with the Trump administration are exempt, as are generic drugs, biosimilars, and related ingredients.

4/2/2026

The CDMO says the pending acquisition of two U.S. drug substance facilities, slated to close in the second or third quarter, positions it for sustained profitable growth.

4/1/2026

The company is growing its RLT production network in the U.S. as part of a planned $23 billion investment in infrastructure over five years.

3/31/2026

The company is strengthening development and manufacturing offerings, says Anil Kane, global head of technical and scientific affairs for Thermo Fisher’s pharma services.

3/30/2026

The South Korean company claims that its Syracuse Bio Campus, a former Bristol Myers Squibb facility, has one of the largest U.S. conjugation capabilities for ADC production.

3/27/2026

The manufacturer of biosimilars will construct Plants 4 and 5 at its Songdo campus in Incheon, with a combined capacity of 180,000 liters.

3/26/2026

With the installation of large-scale stainless steel and smaller single-use bioreactors, Fujifilm Biotechnologies is expanding into drug products and finished goods.

3/25/2026

The Gwinnett County campus will implement a digital-first approach leveraging AI, robotics, and automation to produce biologics primarily for the U.S. market.

3/24/2026

The Chinese CRDMO’s revenue generated from the U.S. market increased $34.3% year-over-year, while Europe and China declined last year compared to 2024.

3/23/2026

By pairing AMTs with underutilized U.S. facilities, APIIC aims to expand domestic manufacturing of critical medicines and strengthen pharmaceutical supply chain.

3/19/2026

As part of its $15 billion investment in China, the drugmaker intends to become the first global biopharma company with end-to-end cell therapy capabilities in the country.

3/19/2026

Chinese production of active pharmaceutical ingredients and key starting materials is putting Americans at risk, according to a bipartisan congressional committee.

3/18/2026

The new biomanufacturing campus in Holly Springs, North Carolina was modelled after a large-scale production site in Hillerød, Denmark, cutting design time by 70%.

3/17/2026

Guidance reflects customer loss due to change in its supply strategy, lower hyaluronic acid revenue from customer, and delayed customer launch that was slated for this year.

3/16/2026

The agency cited the CDMO’s significant violations of current Good Manufacturing Practice regulations for finished pharmaceuticals at Simtra’s Halle/Westfalen facility.

3/13/2026

These therapies are poised to reshape treatment standards this year, from next‑gen metabolic drugs to breakthrough advances in oncology, immunology, and rare diseases.

3/12/2026

The 125,000-square-foot facility, which is slated to be operational in 2027, is where cutting-edge genetic medicine will meet industrial scale, says CEO Chris Murphy.

3/11/2026

The Danish drugmaker received a warning letter from the agency related to a Post-marketing Adverse Drug Experience inspection conducted last month.

3/10/2026

The agency issued a Complete Response Letter for Incyte’s supplemental Biologics License Application, citing inspection findings at Novo Nordisk’s fill-finish facility.

3/9/2026

The divestment of the business to Lone Star Funds enables Lonza’s transformation to become a pure-play contract development and manufacturing organization.

3/6/2026

Big Pharma and contract development and manufacturing organizations are making large capital expenditures to build infrastructure supporting the wildly popular medications.

3/5/2026

Ongoing investments in its Fishers, Indiana and Latina, Italy sites are expanding capacity for high-value products, while the company pivots away from other categories.

3/4/2026

Lilly is struggling to find the talent required for these capital expenditure projects, says Steve Marr, head of the drugmaker’s global facilities delivery parenteral.

3/3/2026

Home to pharma giants Roche and Novartis, the Swiss city along the Rhine River is attracting biotech companies of all sizes that are driving life sciences innovation.

3/2/2026

With the launch of the Wegovy pill in the U.S., the drugmaker is adding manufacturing capacity to its Athlone, Ireland site to support current and future GLP-1 treatments.

2/27/2026

Chris Chen, CEO of WuXi Biologics, discusses his organization’s approach to ensuring consistent quality, reliability, and speed of biologics development and manufacturing.

2/26/2026

Overall, the company’s specialty CDMO business grew in the low-double digits during the first quarter of fiscal 2026, with expectations of mid-teens growth this year.

2/25/2026

The company is selling contract development and manufacturing organization sites in Tennessee, Maryland, and the UK, as well as a cell solutions site in California.